Tag - CASI

Executive Moves

Dr. Barbara Krebs-Pohl joins CASI’s BOD

CASI Pharmaceuticals (NASDAQ: CASI) has announced the appointment of Barbara Krebs-Pohl, PhD, as an independent director to its board of directors (BOD). Dr. Krebs-Pohl brings more than 27 years of leadership experience...

September 2, 2025

Markets

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

BTIG initiated coverage on six companies with “buy” ratings that it believes are undervalued players in the cell therapy space, each developing some variation of autologous CAR-Ts, “off-the-shelf” allogeneic CAR-Ts...

May 17, 2021

Tag - CASI

Dr. Barbara Krebs-Pohl joins CASI’s BOD

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

Subscribe